|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Honda M, Wong SL, Healy MA, Nakajima T,
Watanabe M, Fukuma S, Fukuhara S and Ayanian JZ: Long-term trends
in primary sites of gastric adenocarcinoma in Japan and the United
States. J Cancer. 8:1935–1942. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katanoda K, Hori M, Saito E, Shibata A,
Ito Y, Minami T, Ikeda S, Suzuki T and Matsuda T: Updated trends in
cancer in Japan: Incidence in 1985–2015 and mortality in
1958–2018-A sign of decrease in cancer incidence. J Epidemiol.
31:426–450. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cortes-Ciriano I, Lee S, Park WY, Kim TM
and Park PJ: A molecular portrait of microsatellite instability
across multiple cancers. Nat Commun. 8:151802017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Germano G, Amirouchene-Angelozzi N, Rospo
G and Bardelli A: The clinical impact of the genomic landscape of
mismatch repair-deficient cancers. Cancer Discov. 8:1518–1528.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hampel H, Frankel WL, Martin E, Arnold M,
Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J,
et al: Screening for the Lynch syndrome (hereditary nonpolyposis
colorectal cancer). N Engl J Med. 352:1851–1860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guyot D'Asnières De Salins A, Tachon G,
Cohen R, Karayan-Tapon L, Junca A, Frouin E, Godet J, Evrard C,
Randrian V, Duval A, et al: Discordance between immunochemistry of
mismatch repair proteins and molecular testing of microsatellite
instability in colorectal cancer. ESMO Open. 6:1001202021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y, Shi C, Eisenberg R and
Vnencak-Jones CL: Differences in microsatellite instability
profiles between endometrioid and colorectal cancers: A potential
cause for false-negative results? J Mol Diagn. 19:57–64. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mangold E, Pagenstecher C, Friedl W,
Fischer HP, Merkelbach-Bruse S, Ohlendorf M, Friedrichs N, Aretz S,
Buettner R, Propping P and Mathiak M: Tumours from MSH2 mutation
carriers show loss of MSH2 expression but many tumours from MLH1
mutation carriers exhibit weak positive MLH1 staining. J Pathol.
207:385–395. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beghelli S, de Manzoni G, Barbi S,
Tomezzoli A, Roviello F, Di Gregorio C, Vindigni C, Bortesi L,
Parisi A, Saragoni L, et al: Microsatellite instability in gastric
cancer is associated with better prognosis in only stage II
cancers. Surgery. 139:347–356. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Seo HM, Chang YS, Joo SH, Kim YW, Park YK,
Hong SW and Lee SH: Clinicopathologic characteristics and outcomes
of gastric cancers with the MSI-H phenotype. J Surg Oncol.
99:143–147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ito T, Suzuki O, Kamae N, Tamaru JI, Arai
T, Yamaguchi T, Akagi K, Eguchi H, Okazaki Y, Mochiki E and Ishida
H: Comprehensive analysis of DNA mismatch repair-deficient gastric
cancer in a Japanese hospital-based population. Jpn J Clin Oncol.
51:886–894. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakamura K, Sugano H and Takagi K:
Carcinoma of the stomach in incipient phase: Its histogenesis and
histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI
|
|
18
|
Ishikubo T, Nishimura Y, Yamaguchi K,
Khansuwan U, Arai Y, Kobayashi T, Ohkura Y, Hashiguchi Y, Tanaka Y
and Akagi K: The clinical features of rectal cancers with
high-frequency microsatellite instability (MSI-H) in Japanese
males. Cancer Lett. 216:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yamamoto A, Yamaguchi T, Suzuki O, Ito T,
Chika N, Kamae N, Tamaru JI, Nagai T, Seki H, Arai T, et al:
Prevalence and molecular characteristics of DNA mismatch repair
deficient endometrial cancer in a Japanese hospital-based
population. Jpn J Clin Oncol. 51:60–69. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murphy KM, Zhang S, Geiger T, Hafez MJ,
Bacher J, Berg KD and Eshleman JR: Comparison of the microsatellite
instability analysis system and the Bethesda panel for the
determination of microsatellite instability in colorectal cancers.
J Mol Diagn. 8:305–311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deschoolmeester V, Baay M, Wuyts W, Van
Marck E, Van Damme N, Vermeulen P, Lukaszuk K, Lardon F and
Vermorken JB: Detection of microsatellite instability in colorectal
cancer using an alternative multiplex assay of quasi-monomorphic
mononucleotide markers. J Mol Diagn. 10:154–159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mathiak M, Warneke VS, Behrens HM, Haag J,
Böger C, Krüger S and Röcken C: Clinicopathologic characteristics
of microsatellite in gastric carcinomas revisited: Urgent need for
standardization. Appl Immunohistochem Mol Morphol. 25:12–24. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong SP, Min BS, Kim TI, Cheon JH, Kim NK,
Kim H and Kim WH: The differential impact of microsatellite
instability as a marker of prognosis and tumour response between
colon cancer and rectal cancer. Eur J Cancer. 48:1235–1243. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JY, Shin NR, Kim A, Lee HJ, Park WY,
Kim JY, Lee CH, Huh GY and Park DY: Microsatellite instability
status in gastric cancer: A reappraisal of its clinical
significance and relationship with mucin phenotypes. Korean J
Pathol. 47:28–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arai T, Sakurai U, Sawabe M, Honma N, Aida
J, Ushio Y, Kanazawa N, Kuroiwa K and Takubo K: Frequent
microsatellite instability in papillary and solid-type, poorly
differentiated adenocarcinomas of the stomach. Gastric Cancer.
16:505–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shigeyasu K, Nagasaka T, Mori Y, Yokomichi
N, Kawai T, Fuji T, Kimura K, Umeda Y, Kagawa S, Goel A and
Fujiwara T: Clinical significance of MLH1 methylation and CpG
island methylator phenotype as prognostic markers in patients with
gastric cancer. PLoS One. 10:e01304092015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kazama Y, Watanabe T, Kanazawa T, Tanaka
J, Tanaka T and Nagawa H: Poorly differentiated colorectal
adenocarcinomas show higher rates of microsatellite instability and
promoter methylation of p16 and hMLH1: A study matched for T
classification and tumor location. J Surg Oncol. 97:278–283. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arai T, Matsuda Y, Aida J, Takubo K and
Ishiwata T: Solid-type poorly differentiated adenocarcinoma of the
stomach: Clinicopathological and molecular characteristics and
histogenesis. Gastric Cancer. 22:314–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin SY, Kim JH, Kook MC, Park DY, Ryu KW,
Choi IJ, Noh SH, Kim H and Lee YC: Clinicopathologic features of
submucosal papillary gastric cancer differ from those of other
differentiated-type histologies. Gut Liver. 15:44–52. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alam MR, Abdul-Ghafar J, Yim K, Thakur N,
Lee SH, Jang HJ, Jung CK and Chong Y: Recent applications of
artificial intelligence from histopathologic image-based prediction
of microsatellite instability in solid cancers: A systematic
review. Cancers (Basel). 14:25902022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sugimoto R, Endo M, Osakabe M, Toya Y,
Yanagawa N, Matsumoto T and Sugai T: Immunohistochemical analysis
of mismatch repair gene proteins in early gastric cancer based on
microsatellite status. Digestion. 102:691–700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de la Chapelle A and Hampel H: Clinical
relevance of microsatellite instability in colorectal cancer. J
Clin Oncol. 28:3380–3387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sepulveda AR, Santos AC, Yamaoka Y, Wu L,
Gutierrez O, Kim JG and Graham DY: Marked differences in the
frequency of microsatellite instability in gastric cancer from
different countries. Am J Gastroenterol. 94:3034–3038. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huo X, Xiao X, Zhang S, Du X, Li C, Bai Z
and Chen Z: Characterization and clinical evaluation of
microsatellite instability and loss of heterozygosity in
tumor-related genes in gastric cancer. Oncol Lett. 21:4302021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu G, Qin L, Zhang X, Ye G and Huang T:
Epigenetic silencing of the MLH1 promoter in relation to the
development of gastric cancer and its use as a biomarker for
patients with microsatellite instability: A systematic analysis.
Cell Physiol Biochem. 45:148–162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ho SWT and Tan P: Dissection of gastric
cancer heterogeneity for precision oncology. Cancer Sci.
110:3405–3414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Varley KE, Mutch DG, Edmonston TB,
Goodfellow PJ and Mitra RD: Intra-tumor heterogeneity of MLH1
promoter methylation revealed by deep single molecule bisulfite
sequencing. Nucleic Acids Res. 37:4603–4612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pai RK, Plesec TP, Abdul-Karim FW, Yang B,
Marquard J, Shadrach B and Roma AR: Abrupt loss of MLH1 and PMS2
expression in endometrial carcinoma: Molecular and morphologic
analysis of 6 cases: Molecular and morphologic analysis of 6 cases.
Am J Surg Pathol. 39:993–999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ta RM, Hecht JL and Lin DI: Discordant
loss of mismatch repair proteins in advanced endometrial
endometrioid carcinoma compared to paired primary uterine tumors.
Gynecol Oncol. 151:401–406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus
chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pietrantonio F, Randon G, Di Bartolomeo M,
Luciani A, Chao J, Smyth EC and Petrelli F: Predictive role of
microsatellite instability for PD-1 blockade in patients with
advanced gastric cancer: A meta-analysis of randomized clinical
trials. ESMO Open. 6:1000362021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chao J, Fuchs CS, Shitara K, Tabernero J,
Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, et al:
Assessment of pembrolizumab therapy for the treatment of
microsatellite instability-high gastric or gastroesophageal
junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and
KEYNOTE-062 clinical trials. JAMA Oncol. 7:895–902. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kawakami H, Hironaka S, Esaki T, Chayama
K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano
H, et al: An investigator-initiated phase 2 study of nivolumab plus
low-dose ipilimumab as first-line therapy for microsatellite
instability-high advanced gastric or esophagogastric junction
cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel).
13:8052021. View Article : Google Scholar : PubMed/NCBI
|
